Skip to main content
Caplight Logo









Canton Biologics

Canton Biologics

Private
GuangzhouHealthcare & Life Scienceshttps://cantonbio.com

Last Round

Series C

Sep 13, 2023

Total Funding Raised

$56.1M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Canton Biologics is a biotechnology company that provides contract development and manufacturing organization (CDMO) services for biologic drugs, including monoclonal antibodies, bispecific antibodies, and recombinant proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CDMOcontract development and manufacturing organizationbiologics manufacturingCMCchemistry, manufacturing, and controlsbiotech outsourcingcell line developmentGMP manufacturingfill and finishbiopharmaceutical servicesdrug substance manufacturingmonoclonal antibodiesprocess developmentdrug developmentbiologics platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Canton Biologics Comparables

Compare Canton Biologics with similar companies based on industry and business-model similarity.

Canton Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Bioworkshops
93%
Chime Biologics
92%
MabPlex
89%

Canton Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 13, 2023

Key People

Founding team and executive leadership

Xiao Shen

CEO

Executive Team

Canton Biologics Investors

Notable investors and investment history

Canton Biologics investors
InvestorRounds
Guangdong Technology Financial GroupSeries C
SDIC Venture CapitalSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 26, 2026

    Open roles increased to 25, 2.3x the trailing average.

  • Oct 12, 2026

    Open roles increased to 19, 49% of headcount.

Canton Biologics Filings

Explore SEC and related filing metadata, where available.

Canton Biologics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Canton Biologics's valuation, stock price, and market status.

Is Canton Biologics a public or private company?

Canton Biologics is a private company.

What is the current stock price of Canton Biologics?

Canton Biologics is a private company, so its shares have no public market price. Caplight tracks Canton Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Canton Biologics worth (valuation)?

Valuation information for Canton Biologics is not publicly available.

Can I buy Canton Biologics stock?

Canton Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Canton Biologics's last funding round?

Canton Biologics's most recent funding round was Series C on September 13, 2023.

Who are the main investors in Canton Biologics?

Key investors in Canton Biologics include SDIC Venture Capital.

Will Canton Biologics IPO soon?

No public IPO plans have been announced for Canton Biologics.

How can I track Canton Biologics secondary market activity?

Caplight tracks bids, offers, and trades in Canton Biologics's shares on secondary markets.

Firmographic Details

HeadquartersGuangzhou
Employee Range39
Year Founded2016
Last FundingSep 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?